Cargando…
Spironolactone Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Rats
Spironolactone (SPR) has been shown to protect diabetic cardiomyopathy (DCM), but the specific mechanisms are not fully understood. Here, we determined the cardioprotective role of SPR in diabetic mice and further explored the potential mechanisms in both in vivo and in vitro models. Streptozotocin-...
Autores principales: | Liu, Wenjuan, Gong, Wei, He, Min, Liu, Yemei, Yang, Yeping, Wang, Meng, Wu, Meng, Guo, Shizhe, Yu, Yifei, Wang, Xuanchun, Sun, Fei, Li, Yiming, Zhou, Linuo, Qin, Shengmei, Zhang, Zhaoyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204188/ https://www.ncbi.nlm.nih.gov/pubmed/30406151 http://dx.doi.org/10.1155/2018/9232065 |
Ejemplares similares
-
Exogenous Pancreatic Kallikrein Improves Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetes
por: Wu, Meng, et al.
Publicado: (2018) -
The association of erythrocyte sedimentation rate, high-sensitivity C-reactive protein and diabetic kidney disease in patients with type 2 diabetes
por: Guo, Shizhe, et al.
Publicado: (2020) -
Anemia is a risk factor for rapid eGFR decline in type 2 diabetes
por: Xie, Lijie, et al.
Publicado: (2023) -
Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice
por: Wu, Bin, et al.
Publicado: (2017) -
Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan
por: Makhlough, Atieh, et al.
Publicado: (2014)